319 related articles for article (PubMed ID: 20551193)
1. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
3. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
4. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
Fukunishi M; Kikkawa M; Hamana K; Onodera T; Matsuzaki K; Matsumoto Y; Hara J
J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407
[TBL] [Abstract][Full Text] [Related]
5. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S; Kawashima H; Kashiwagi Y; Hoshika A
Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C; Yeung RS; Chahal N; McCrindle BW
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[TBL] [Abstract][Full Text] [Related]
11. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J; Ebata R; Jibiki T; Yasukawa K; Saito H; Terai M
J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
[TBL] [Abstract][Full Text] [Related]
12. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[TBL] [Abstract][Full Text] [Related]
13. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Liang CD; Wang CL; Yu HR; Hwang KP; Yang KD
Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
[TBL] [Abstract][Full Text] [Related]
14. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT
J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin failure and retreatment in Kawasaki disease.
Durongpisitkul K; Soongswang J; Laohaprasitiporn D; Nana A; Prachuabmoh C; Kangkagate C
Pediatr Cardiol; 2003; 24(2):145-8. PubMed ID: 12457253
[TBL] [Abstract][Full Text] [Related]
16. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
17. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
18. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
19. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Yang KD; Liang CD; Bong CN; Yu HR; Wang L; Wang CL
Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]